Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaci.2018.08.050 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Incidence and Predictors of Clinical Outcomes in Real-Life Patients With Atrial Fibrillation Treated With Oral Factor Xa Inhibitors: The Follow-Up Results of the ANATOLIA-AF Study.
Clin Cardiol
January 2025
Department of Cardiology, Firat University Hospital, Elazig, Türkiye.
Objective: The main objective of this study is to determine the incidence and predictors of clinical outcomes in patients with AF treated with factor Xa inhibitors in a real-world setting.
Methods: The present study was a multicentre and observational study that included patients with AF who were treated with factor Xa inhibitors. The primary outcome was the composite of ischemic stroke, TIA, systemic embolism, major bleeding, and all-cause mortality.
Real-world clinical experience with secukinumab in psoriatic arthritis: an observational study and a literature review.
Reumatismo
January 2025
Unit of Dermatology, Department of Medicine and Aging Science, G. d'Annunzio University, Chieti.
Objective: Psoriatic arthritis (PsA) can be treated with biological drugs targeting IL-17A, such as secukinumab, with good responses and long-term positive outcomes in clinical studies.
Methods: An observational study was conducted on adult subjects with PsA and comorbidities, treated with secukinumab after prior therapy with conventional disease-modifying anti-rheumatic drugs or biological agents that were discontinued due to lack of efficacy or adverse drug reactions. Patients were followed up with clinical visits at 3, 6, 9, and 12 months and evaluated for disease activity, pain, and quality of life, with respect to values recorded at baseline.
Update on Pulmonary Toxicity Induced by New Breast Cancer Treatments.
Breast Cancer (Dove Med Press)
January 2025
GOIRC (Gruppo Oncologico Italiano di Ricerca Clinica), Parma, Italy.
In recent years, new anticancer drugs have been investigated and approved for the treatment of breast cancer based on improved survival outcomes. However, these new treatments have specific class-related side effects. Pulmonary toxicity has been identified as an adverse event of special interest with everolimus, and is becoming an increasingly significant clinical challenge with the recent approval of trastuzumab deruxtecan.
View Article and Find Full Text PDFLong-term sublingual bacterial immunotherapy prevents ear, nose and throat infections: A real-life study.
SAGE Open Med
January 2025
Allergy and Immunology Service Hospitale Maternidade Therezinha de Jesus, Juiz de Fora, Brazil.
Objective: Bacterial extracts have been used for many years to prevent airway infections. Recent findings suggest that immunity can be trained by inducing an immunological memory in both the innate and acquired immune response. This real-life observational study investigated the potential of sublingual bacterial immunotherapy in the prevention of ear, nose, and throat infections.
View Article and Find Full Text PDFNeurodevelopmental and Growth Follow-Up of an Infant Exposed to Rosuvastatin by Lactation: A Case Report.
Breastfeed Med
January 2025
Social Pediatrics Doctorate Program, Institute of Health Sciences, Istanbul University, Istanbul, Turkiye.
Usage of some medications while breastfeeding is supported with many clinical studies and proven to be safe for the mother-infant dyad, whereas knowledge on many medications' safety depends on pharmacokinetic data that are supported with only case series of real-life results. As data on rosuvastatin usage are limited, we present our case report with safe use of rosuvastatin in a breastfeeding mother of a 13-month-old infant. Pretreatment assessments of the infant were performed.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!